Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial

Michael Masetti, Alexander Nieto, Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C. Thuss-Patience, Jorge Riera-Knorrenschild, Eray Goekkurt, Tobias Nicolaas Dechow, Thomas Jens Ettrich, Ralf Dieter Hofheinz, Kim Barbara Luley, Daniel Pink, Udo Lindig, Gunnar Folprecht, Gunter Schuch, Michael Bitzer, Volker Heinemann, Stefan Angermeier, Claus Bolling, Maria Loose, Sabine Junge, Claudia Pauligk, Salah-Eddin Al-Batran, Alexander Stein, Joseph Tintelnot

Open source

DOI: 10.1016/j.ejca.2026.117037
Published: 2026-11
Container: European Journal of Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2026.117037,
  title = {Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial},
  author = {Michael Masetti and Alexander Nieto and Sylvie Lorenzen and Thorsten Oliver Goetze and Peter C. Thuss-Patience and Jorge Riera-Knorrenschild and Eray Goekkurt and Tobias Nicolaas Dechow and Thomas Jens Ettrich and Ralf Dieter Hofheinz and Kim Barbara Luley and Daniel Pink and Udo Lindig and Gunnar Folprecht and Gunter Schuch and Michael Bitzer and Volker Heinemann and Stefan Angermeier and Claus Bolling and Maria Loose and Sabine Junge and Claudia Pauligk and Salah-Eddin Al-Batran and Alexander Stein and Joseph Tintelnot},
  year = {2026},
  journal = {European Journal of Cancer},
  doi = {10.1016/j.ejca.2026.117037},
  url = {https://doi.org/10.1016/j.ejca.2026.117037}
}

RIS

TY  - JOUR
TI  - Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial
AU  - Michael Masetti
AU  - Alexander Nieto
AU  - Sylvie Lorenzen
AU  - Thorsten Oliver Goetze
AU  - Peter C. Thuss-Patience
AU  - Jorge Riera-Knorrenschild
AU  - Eray Goekkurt
AU  - Tobias Nicolaas Dechow
AU  - Thomas Jens Ettrich
AU  - Ralf Dieter Hofheinz
AU  - Kim Barbara Luley
AU  - Daniel Pink
AU  - Udo Lindig
AU  - Gunnar Folprecht
AU  - Gunter Schuch
AU  - Michael Bitzer
AU  - Volker Heinemann
AU  - Stefan Angermeier
AU  - Claus Bolling
AU  - Maria Loose
AU  - Sabine Junge
AU  - Claudia Pauligk
AU  - Salah-Eddin Al-Batran
AU  - Alexander Stein
AU  - Joseph Tintelnot
PY  - 2026
JO  - European Journal of Cancer
DO  - 10.1016/j.ejca.2026.117037
UR  - https://doi.org/10.1016/j.ejca.2026.117037
ER  -

APA

Masetti, M., Nieto, A., Lorenzen, S., Goetze, T. O., Thuss-Patience, P. C., Riera-Knorrenschild, J., Goekkurt, E., Dechow, T. N., Ettrich, T. J., Hofheinz, R. D., Luley, K. B., Pink, D., Lindig, U., Folprecht, G., Schuch, G., Bitzer, M., Heinemann, V., Angermeier, S., Bolling, C., Loose, M., Junge, S., Pauligk, C., Al-Batran, S., Stein, A., & Tintelnot, J. (2026). Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117037

Source records

crossref · retrieved 2026-09-24T20:02:57.739Z